NCT04587128 2026-02-05Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCUniversity of Wisconsin, MadisonPhase 2 Active not recruiting34 enrolled
NCT06106308 2026-01-12Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationCardiff OncologyPhase 2 Active not recruiting113 enrolled